nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—Doxorubicin—pancreatic cancer	0.212	1	CrCtD
Epirubicin—Topoisomerase Inhibitors—Irinotecan—pancreatic cancer	0.119	0.407	CiPCiCtD
Epirubicin—Anthracyclines—Doxorubicin—pancreatic cancer	0.114	0.389	CiPCiCtD
Epirubicin—liver cancer—pancreatic cancer	0.0933	0.579	CtDrD
Epirubicin—stomach cancer—pancreatic cancer	0.0679	0.421	CtDrD
Epirubicin—Topoisomerase Inhibitors—Doxorubicin—pancreatic cancer	0.0594	0.203	CiPCiCtD
Epirubicin—DHCR7—Tamoxifen—pancreatic cancer	0.0549	0.394	CbGbCtD
Epirubicin—Idarubicin—Doxorubicin—pancreatic cancer	0.0447	0.333	CrCrCtD
Epirubicin—Daunorubicin—Doxorubicin—pancreatic cancer	0.0447	0.333	CrCrCtD
Epirubicin—Valrubicin—Doxorubicin—pancreatic cancer	0.0447	0.333	CrCrCtD
Epirubicin—DHCR7—Doxorubicin—pancreatic cancer	0.023	0.165	CbGbCtD
Epirubicin—YWHAG—Doxorubicin—pancreatic cancer	0.023	0.165	CbGbCtD
Epirubicin—AURKA—Doxorubicin—pancreatic cancer	0.023	0.165	CbGbCtD
Epirubicin—ABCC1—Irinotecan—pancreatic cancer	0.00475	0.034	CbGbCtD
Epirubicin—TOP2A—Doxorubicin—pancreatic cancer	0.00468	0.0335	CbGbCtD
Epirubicin—ABCC1—Docetaxel—pancreatic cancer	0.00348	0.0249	CbGbCtD
Epirubicin—ABCC1—Doxorubicin—pancreatic cancer	0.00259	0.0186	CbGbCtD
Epirubicin—CHD1—Topotecan—Irinotecan—pancreatic cancer	0.00037	0.417	CbGdCrCtD
Epirubicin—CHD1—pancreas—pancreatic cancer	0.000184	0.156	CbGeAlD
Epirubicin—DHCR7—islet of Langerhans—pancreatic cancer	0.000176	0.15	CbGeAlD
Epirubicin—YWHAG—islet of Langerhans—pancreatic cancer	0.000162	0.137	CbGeAlD
Epirubicin—AURKA—digestive system—pancreatic cancer	0.000127	0.108	CbGeAlD
Epirubicin—DHCR7—pancreas—pancreatic cancer	0.000124	0.105	CbGeAlD
Epirubicin—AURKA—Topotecan—Irinotecan—pancreatic cancer	0.000122	0.137	CbGdCrCtD
Epirubicin—YWHAG—pancreas—pancreatic cancer	0.000114	0.0966	CbGeAlD
Epirubicin—DHCR7—digestive system—pancreatic cancer	0.000106	0.09	CbGeAlD
Epirubicin—YWHAG—digestive system—pancreatic cancer	9.71e-05	0.0825	CbGeAlD
Epirubicin—UGT2B7—digestive system—pancreatic cancer	8.77e-05	0.0745	CbGeAlD
Epirubicin—CHD1—Daunorubicin—Doxorubicin—pancreatic cancer	8.04e-05	0.0907	CbGdCrCtD
Epirubicin—CHD1—Idarubicin—Doxorubicin—pancreatic cancer	8.04e-05	0.0907	CbGdCrCtD
Epirubicin—TOP2A—Topotecan—Irinotecan—pancreatic cancer	4.64e-05	0.0524	CbGdCrCtD
Epirubicin—TOP2A—Paclitaxel—Docetaxel—pancreatic cancer	3.26e-05	0.0368	CbGdCrCtD
Epirubicin—TOP2A—Gefitinib—Erlotinib—pancreatic cancer	3.13e-05	0.0353	CbGdCrCtD
Epirubicin—AURKA—Cytarabine—Gemcitabine—pancreatic cancer	3.08e-05	0.0348	CbGdCrCtD
Epirubicin—AURKA—Idarubicin—Doxorubicin—pancreatic cancer	2.64e-05	0.0298	CbGdCrCtD
Epirubicin—AURKA—Daunorubicin—Doxorubicin—pancreatic cancer	2.64e-05	0.0298	CbGdCrCtD
Epirubicin—TOP2A—Cytarabine—Gemcitabine—pancreatic cancer	1.18e-05	0.0133	CbGdCrCtD
Epirubicin—TOP2A—Daunorubicin—Doxorubicin—pancreatic cancer	1.01e-05	0.0114	CbGdCrCtD
Epirubicin—TOP2A—Idarubicin—Doxorubicin—pancreatic cancer	1.01e-05	0.0114	CbGdCrCtD
Epirubicin—TOP2A—Azacitidine—Gemcitabine—pancreatic cancer	8.44e-06	0.00952	CbGdCrCtD
Epirubicin—Somnolence—Fluorouracil—pancreatic cancer	8.18e-06	0.000178	CcSEcCtD
Epirubicin—Face oedema—Doxorubicin—pancreatic cancer	8.14e-06	0.000177	CcSEcCtD
Epirubicin—Erythema—Docetaxel—pancreatic cancer	8.14e-06	0.000177	CcSEcCtD
Epirubicin—Malnutrition—Docetaxel—pancreatic cancer	8.14e-06	0.000177	CcSEcCtD
Epirubicin—Decreased appetite—Gemcitabine—pancreatic cancer	8.14e-06	0.000177	CcSEcCtD
Epirubicin—Dyspepsia—Fluorouracil—pancreatic cancer	8.1e-06	0.000176	CcSEcCtD
Epirubicin—Nausea—Tamoxifen—pancreatic cancer	8.09e-06	0.000176	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	8.08e-06	0.000176	CcSEcCtD
Epirubicin—Fatigue—Gemcitabine—pancreatic cancer	8.07e-06	0.000176	CcSEcCtD
Epirubicin—Cardiac arrest—Doxorubicin—pancreatic cancer	8.02e-06	0.000175	CcSEcCtD
Epirubicin—Pain—Gemcitabine—pancreatic cancer	8e-06	0.000174	CcSEcCtD
Epirubicin—Constipation—Gemcitabine—pancreatic cancer	8e-06	0.000174	CcSEcCtD
Epirubicin—Nausea—Erlotinib—pancreatic cancer	8e-06	0.000174	CcSEcCtD
Epirubicin—Decreased appetite—Fluorouracil—pancreatic cancer	8e-06	0.000174	CcSEcCtD
Epirubicin—Mood swings—Doxorubicin—pancreatic cancer	7.99e-06	0.000174	CcSEcCtD
Epirubicin—Diarrhoea—Sunitinib—pancreatic cancer	7.98e-06	0.000174	CcSEcCtD
Epirubicin—Dysgeusia—Docetaxel—pancreatic cancer	7.97e-06	0.000173	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	7.94e-06	0.000173	CcSEcCtD
Epirubicin—Ataxia—Doxorubicin—pancreatic cancer	7.93e-06	0.000173	CcSEcCtD
Epirubicin—Feeling abnormal—Irinotecan—pancreatic cancer	7.92e-06	0.000172	CcSEcCtD
Epirubicin—Blood creatinine increased—Doxorubicin—pancreatic cancer	7.9e-06	0.000172	CcSEcCtD
Epirubicin—Back pain—Docetaxel—pancreatic cancer	7.87e-06	0.000171	CcSEcCtD
Epirubicin—Pain—Fluorouracil—pancreatic cancer	7.87e-06	0.000171	CcSEcCtD
Epirubicin—Gastrointestinal pain—Irinotecan—pancreatic cancer	7.86e-06	0.000171	CcSEcCtD
Epirubicin—Dehydration—Doxorubicin—pancreatic cancer	7.84e-06	0.000171	CcSEcCtD
Epirubicin—Muscle spasms—Docetaxel—pancreatic cancer	7.82e-06	0.00017	CcSEcCtD
Epirubicin—Liver function test abnormal—Doxorubicin—pancreatic cancer	7.79e-06	0.000169	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—HRAS—pancreatic cancer	7.75e-06	0.000574	CbGpPWpGaD
Epirubicin—PLA2G4A—Phospholipid metabolism—PIK3CA—pancreatic cancer	7.73e-06	0.000573	CbGpPWpGaD
Epirubicin—Dry skin—Doxorubicin—pancreatic cancer	7.73e-06	0.000168	CcSEcCtD
Epirubicin—Dizziness—Sunitinib—pancreatic cancer	7.71e-06	0.000168	CcSEcCtD
Epirubicin—Feeling abnormal—Gemcitabine—pancreatic cancer	7.71e-06	0.000168	CcSEcCtD
Epirubicin—Abdominal pain upper—Doxorubicin—pancreatic cancer	7.7e-06	0.000168	CcSEcCtD
Epirubicin—Orthostatic hypotension—Doxorubicin—pancreatic cancer	7.7e-06	0.000168	CcSEcCtD
Epirubicin—Hypokalaemia—Doxorubicin—pancreatic cancer	7.68e-06	0.000167	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	7.64e-06	0.000566	CbGpPWpGaD
Epirubicin—Breast disorder—Doxorubicin—pancreatic cancer	7.62e-06	0.000166	CcSEcCtD
Epirubicin—Abdominal pain—Irinotecan—pancreatic cancer	7.6e-06	0.000165	CcSEcCtD
Epirubicin—Body temperature increased—Irinotecan—pancreatic cancer	7.6e-06	0.000165	CcSEcCtD
Epirubicin—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	7.59e-06	0.000165	CcSEcCtD
Epirubicin—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	7.59e-06	0.000165	CcSEcCtD
Epirubicin—Feeling abnormal—Fluorouracil—pancreatic cancer	7.58e-06	0.000165	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—TERT—pancreatic cancer	7.57e-06	0.000561	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	7.55e-06	0.00056	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PRSS1—pancreatic cancer	7.55e-06	0.000559	CbGpPWpGaD
Epirubicin—Nasopharyngitis—Doxorubicin—pancreatic cancer	7.54e-06	0.000164	CcSEcCtD
Epirubicin—Anaemia—Docetaxel—pancreatic cancer	7.52e-06	0.000164	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	7.49e-06	0.000555	CbGpPWpGaD
Epirubicin—Gastritis—Doxorubicin—pancreatic cancer	7.46e-06	0.000162	CcSEcCtD
Epirubicin—Muscular weakness—Doxorubicin—pancreatic cancer	7.44e-06	0.000162	CcSEcCtD
Epirubicin—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	7.44e-06	0.000162	CcSEcCtD
Epirubicin—Vomiting—Sunitinib—pancreatic cancer	7.42e-06	0.000161	CcSEcCtD
Epirubicin—AURKA—Cell Cycle, Mitotic—MYC—pancreatic cancer	7.41e-06	0.000549	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—CDKN2A—pancreatic cancer	7.41e-06	0.000549	CbGpPWpGaD
Epirubicin—Body temperature increased—Gemcitabine—pancreatic cancer	7.4e-06	0.000161	CcSEcCtD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	7.36e-06	0.000545	CbGpPWpGaD
Epirubicin—Rash—Sunitinib—pancreatic cancer	7.35e-06	0.00016	CcSEcCtD
Epirubicin—Dermatitis—Sunitinib—pancreatic cancer	7.35e-06	0.00016	CcSEcCtD
Epirubicin—Abdominal distension—Doxorubicin—pancreatic cancer	7.34e-06	0.00016	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—SHH—pancreatic cancer	7.33e-06	0.000543	CbGpPWpGaD
Epirubicin—Urticaria—Fluorouracil—pancreatic cancer	7.31e-06	0.000159	CcSEcCtD
Epirubicin—Headache—Sunitinib—pancreatic cancer	7.31e-06	0.000159	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—TYMP—pancreatic cancer	7.3e-06	0.000541	CbGpPWpGaD
Epirubicin—Syncope—Docetaxel—pancreatic cancer	7.3e-06	0.000159	CcSEcCtD
Epirubicin—Asthma—Doxorubicin—pancreatic cancer	7.29e-06	0.000159	CcSEcCtD
Epirubicin—Influenza—Doxorubicin—pancreatic cancer	7.29e-06	0.000159	CcSEcCtD
Epirubicin—Dysphagia—Doxorubicin—pancreatic cancer	7.29e-06	0.000159	CcSEcCtD
Epirubicin—Leukopenia—Docetaxel—pancreatic cancer	7.28e-06	0.000159	CcSEcCtD
Epirubicin—Body temperature increased—Fluorouracil—pancreatic cancer	7.27e-06	0.000158	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—IAPP—pancreatic cancer	7.23e-06	0.000536	CbGpPWpGaD
Epirubicin—Eosinophilia—Doxorubicin—pancreatic cancer	7.22e-06	0.000157	CcSEcCtD
Epirubicin—Palpitations—Docetaxel—pancreatic cancer	7.19e-06	0.000157	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—TYMP—pancreatic cancer	7.16e-06	0.00053	CbGpPWpGaD
Epirubicin—Loss of consciousness—Docetaxel—pancreatic cancer	7.15e-06	0.000156	CcSEcCtD
Epirubicin—Pancreatitis—Doxorubicin—pancreatic cancer	7.15e-06	0.000156	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—DTX1—pancreatic cancer	7.14e-06	0.000529	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SSTR3—pancreatic cancer	7.14e-06	0.000529	CbGpPWpGaD
Epirubicin—Cough—Docetaxel—pancreatic cancer	7.1e-06	0.000155	CcSEcCtD
Epirubicin—Angina pectoris—Doxorubicin—pancreatic cancer	7.1e-06	0.000155	CcSEcCtD
Epirubicin—Hypersensitivity—Irinotecan—pancreatic cancer	7.08e-06	0.000154	CcSEcCtD
Epirubicin—Convulsion—Docetaxel—pancreatic cancer	7.05e-06	0.000153	CcSEcCtD
Epirubicin—Hypertension—Docetaxel—pancreatic cancer	7.03e-06	0.000153	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	7.02e-06	0.00052	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PIK3CG—pancreatic cancer	7.01e-06	0.00052	CbGpPWpGaD
Epirubicin—Bronchitis—Doxorubicin—pancreatic cancer	7.01e-06	0.000153	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	7.01e-06	0.000519	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CCND1—pancreatic cancer	7e-06	0.000518	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—SRC—pancreatic cancer	6.98e-06	0.000517	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PTHLH—pancreatic cancer	6.94e-06	0.000514	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PTCH1—pancreatic cancer	6.94e-06	0.000514	CbGpPWpGaD
Epirubicin—Chest pain—Docetaxel—pancreatic cancer	6.93e-06	0.000151	CcSEcCtD
Epirubicin—Arthralgia—Docetaxel—pancreatic cancer	6.93e-06	0.000151	CcSEcCtD
Epirubicin—Myalgia—Docetaxel—pancreatic cancer	6.93e-06	0.000151	CcSEcCtD
Epirubicin—Nausea—Sunitinib—pancreatic cancer	6.93e-06	0.000151	CcSEcCtD
Epirubicin—Pancytopenia—Doxorubicin—pancreatic cancer	6.92e-06	0.000151	CcSEcCtD
Epirubicin—Asthenia—Irinotecan—pancreatic cancer	6.89e-06	0.00015	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	6.88e-06	0.00051	CbGpPWpGaD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	6.88e-06	0.00015	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	6.87e-06	0.000509	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SSTR1—pancreatic cancer	6.85e-06	0.000507	CbGpPWpGaD
Epirubicin—ABCC1—Disease—DTX4—pancreatic cancer	6.83e-06	0.000506	CbGpPWpGaD
Epirubicin—Neutropenia—Doxorubicin—pancreatic cancer	6.82e-06	0.000148	CcSEcCtD
Epirubicin—Dysuria—Doxorubicin—pancreatic cancer	6.82e-06	0.000148	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—pancreatic cancer	6.79e-06	0.000503	CbGpPWpGaD
Epirubicin—Hypersensitivity—Fluorouracil—pancreatic cancer	6.78e-06	0.000148	CcSEcCtD
Epirubicin—Dry mouth—Docetaxel—pancreatic cancer	6.78e-06	0.000147	CcSEcCtD
Epirubicin—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	6.77e-06	0.000147	CcSEcCtD
Epirubicin—DHCR7—Metabolism—PPARG—pancreatic cancer	6.77e-06	0.000501	CbGpPWpGaD
Epirubicin—Pollakiuria—Doxorubicin—pancreatic cancer	6.73e-06	0.000147	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—PPY—pancreatic cancer	6.72e-06	0.000497	CbGpPWpGaD
Epirubicin—Asthenia—Gemcitabine—pancreatic cancer	6.72e-06	0.000146	CcSEcCtD
Epirubicin—Confusional state—Docetaxel—pancreatic cancer	6.7e-06	0.000146	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	6.66e-06	0.000493	CbGpPWpGaD
Epirubicin—Photosensitivity reaction—Doxorubicin—pancreatic cancer	6.65e-06	0.000145	CcSEcCtD
Epirubicin—ABCC1—Disease—PPP2R5B—pancreatic cancer	6.64e-06	0.000492	CbGpPWpGaD
Epirubicin—Anaphylactic shock—Docetaxel—pancreatic cancer	6.64e-06	0.000145	CcSEcCtD
Epirubicin—Oedema—Docetaxel—pancreatic cancer	6.64e-06	0.000145	CcSEcCtD
Epirubicin—Weight increased—Doxorubicin—pancreatic cancer	6.63e-06	0.000144	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—MYC—pancreatic cancer	6.62e-06	0.000491	CbGpPWpGaD
Epirubicin—Pruritus—Gemcitabine—pancreatic cancer	6.62e-06	0.000144	CcSEcCtD
Epirubicin—Infection—Docetaxel—pancreatic cancer	6.6e-06	0.000144	CcSEcCtD
Epirubicin—Weight decreased—Doxorubicin—pancreatic cancer	6.59e-06	0.000144	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—SSTR2—pancreatic cancer	6.59e-06	0.000488	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—RB1—pancreatic cancer	6.59e-06	0.000488	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—PLAU—pancreatic cancer	6.58e-06	0.000488	CbGpPWpGaD
Epirubicin—Hyperglycaemia—Doxorubicin—pancreatic cancer	6.58e-06	0.000143	CcSEcCtD
Epirubicin—Diarrhoea—Irinotecan—pancreatic cancer	6.57e-06	0.000143	CcSEcCtD
Epirubicin—ABCC1—Metabolism—ARG2—pancreatic cancer	6.54e-06	0.000485	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	6.54e-06	0.000485	CbGpPWpGaD
Epirubicin—Pneumonia—Doxorubicin—pancreatic cancer	6.54e-06	0.000142	CcSEcCtD
Epirubicin—Shock—Docetaxel—pancreatic cancer	6.53e-06	0.000142	CcSEcCtD
Epirubicin—Nervous system disorder—Docetaxel—pancreatic cancer	6.51e-06	0.000142	CcSEcCtD
Epirubicin—Pruritus—Fluorouracil—pancreatic cancer	6.51e-06	0.000142	CcSEcCtD
Epirubicin—Thrombocytopenia—Docetaxel—pancreatic cancer	6.5e-06	0.000142	CcSEcCtD
Epirubicin—Drowsiness—Doxorubicin—pancreatic cancer	6.5e-06	0.000141	CcSEcCtD
Epirubicin—Infestation—Doxorubicin—pancreatic cancer	6.5e-06	0.000141	CcSEcCtD
Epirubicin—Infestation NOS—Doxorubicin—pancreatic cancer	6.5e-06	0.000141	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	6.49e-06	0.000481	CbGpPWpGaD
Epirubicin—Tachycardia—Docetaxel—pancreatic cancer	6.48e-06	0.000141	CcSEcCtD
Epirubicin—Skin disorder—Docetaxel—pancreatic cancer	6.45e-06	0.00014	CcSEcCtD
Epirubicin—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	6.44e-06	0.00014	CcSEcCtD
Epirubicin—Diarrhoea—Gemcitabine—pancreatic cancer	6.4e-06	0.000139	CcSEcCtD
Epirubicin—ABCC1—Disease—HEY2—pancreatic cancer	6.4e-06	0.000474	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—TP53—pancreatic cancer	6.39e-06	0.000474	CbGpPWpGaD
Epirubicin—Renal failure—Doxorubicin—pancreatic cancer	6.39e-06	0.000139	CcSEcCtD
Epirubicin—Neuropathy peripheral—Doxorubicin—pancreatic cancer	6.37e-06	0.000139	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—CCKBR—pancreatic cancer	6.37e-06	0.000472	CbGpPWpGaD
Epirubicin—Dizziness—Irinotecan—pancreatic cancer	6.35e-06	0.000138	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—SST—pancreatic cancer	6.35e-06	0.00047	CbGpPWpGaD
Epirubicin—Stomatitis—Doxorubicin—pancreatic cancer	6.34e-06	0.000138	CcSEcCtD
Epirubicin—Jaundice—Doxorubicin—pancreatic cancer	6.34e-06	0.000138	CcSEcCtD
Epirubicin—Anorexia—Docetaxel—pancreatic cancer	6.33e-06	0.000138	CcSEcCtD
Epirubicin—Urinary tract infection—Doxorubicin—pancreatic cancer	6.32e-06	0.000138	CcSEcCtD
Epirubicin—Conjunctivitis—Doxorubicin—pancreatic cancer	6.32e-06	0.000138	CcSEcCtD
Epirubicin—Diarrhoea—Fluorouracil—pancreatic cancer	6.3e-06	0.000137	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—CCND1—pancreatic cancer	6.26e-06	0.000463	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	6.24e-06	0.000462	CbGpPWpGaD
Epirubicin—Sweating—Doxorubicin—pancreatic cancer	6.23e-06	0.000136	CcSEcCtD
Epirubicin—Hypotension—Docetaxel—pancreatic cancer	6.21e-06	0.000135	CcSEcCtD
Epirubicin—Haematuria—Doxorubicin—pancreatic cancer	6.2e-06	0.000135	CcSEcCtD
Epirubicin—DHCR7—Metabolism—PIK3CD—pancreatic cancer	6.17e-06	0.000457	CbGpPWpGaD
Epirubicin—Hepatobiliary disease—Doxorubicin—pancreatic cancer	6.15e-06	0.000134	CcSEcCtD
Epirubicin—Epistaxis—Doxorubicin—pancreatic cancer	6.13e-06	0.000133	CcSEcCtD
Epirubicin—Vomiting—Irinotecan—pancreatic cancer	6.11e-06	0.000133	CcSEcCtD
Epirubicin—Sinusitis—Doxorubicin—pancreatic cancer	6.1e-06	0.000133	CcSEcCtD
Epirubicin—Dizziness—Fluorouracil—pancreatic cancer	6.09e-06	0.000132	CcSEcCtD
Epirubicin—Agranulocytosis—Doxorubicin—pancreatic cancer	6.07e-06	0.000132	CcSEcCtD
Epirubicin—Rash—Irinotecan—pancreatic cancer	6.06e-06	0.000132	CcSEcCtD
Epirubicin—Dermatitis—Irinotecan—pancreatic cancer	6.05e-06	0.000132	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	6.05e-06	0.000132	CcSEcCtD
Epirubicin—Headache—Irinotecan—pancreatic cancer	6.02e-06	0.000131	CcSEcCtD
Epirubicin—Insomnia—Docetaxel—pancreatic cancer	6.01e-06	0.000131	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—DTX4—pancreatic cancer	5.99e-06	0.000443	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—GLI1—pancreatic cancer	5.99e-06	0.000443	CbGpPWpGaD
Epirubicin—Paraesthesia—Docetaxel—pancreatic cancer	5.96e-06	0.00013	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	5.96e-06	0.000442	CbGpPWpGaD
Epirubicin—Vomiting—Gemcitabine—pancreatic cancer	5.95e-06	0.00013	CcSEcCtD
Epirubicin—Bradycardia—Doxorubicin—pancreatic cancer	5.94e-06	0.000129	CcSEcCtD
Epirubicin—ABCC1—Disease—HEY1—pancreatic cancer	5.92e-06	0.000439	CbGpPWpGaD
Epirubicin—Dyspnoea—Docetaxel—pancreatic cancer	5.92e-06	0.000129	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	5.91e-06	0.000438	CbGpPWpGaD
Epirubicin—Somnolence—Docetaxel—pancreatic cancer	5.9e-06	0.000129	CcSEcCtD
Epirubicin—Rash—Gemcitabine—pancreatic cancer	5.9e-06	0.000128	CcSEcCtD
Epirubicin—Dermatitis—Gemcitabine—pancreatic cancer	5.9e-06	0.000128	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—RB1—pancreatic cancer	5.89e-06	0.000436	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GLP1R—pancreatic cancer	5.88e-06	0.000436	CbGpPWpGaD
Epirubicin—Haemoglobin—Doxorubicin—pancreatic cancer	5.86e-06	0.000128	CcSEcCtD
Epirubicin—Headache—Gemcitabine—pancreatic cancer	5.86e-06	0.000128	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—CNR1—pancreatic cancer	5.86e-06	0.000434	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—PIK3CG—pancreatic cancer	5.86e-06	0.000434	CbGpPWpGaD
Epirubicin—Vomiting—Fluorouracil—pancreatic cancer	5.85e-06	0.000127	CcSEcCtD
Epirubicin—Rhinitis—Doxorubicin—pancreatic cancer	5.85e-06	0.000127	CcSEcCtD
Epirubicin—Dyspepsia—Docetaxel—pancreatic cancer	5.85e-06	0.000127	CcSEcCtD
Epirubicin—Hepatitis—Doxorubicin—pancreatic cancer	5.83e-06	0.000127	CcSEcCtD
Epirubicin—Haemorrhage—Doxorubicin—pancreatic cancer	5.83e-06	0.000127	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—NRP1—pancreatic cancer	5.82e-06	0.000431	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PPP2R5B—pancreatic cancer	5.82e-06	0.000431	CbGpPWpGaD
Epirubicin—Hypoaesthesia—Doxorubicin—pancreatic cancer	5.81e-06	0.000126	CcSEcCtD
Epirubicin—Rash—Fluorouracil—pancreatic cancer	5.8e-06	0.000126	CcSEcCtD
Epirubicin—Dermatitis—Fluorouracil—pancreatic cancer	5.8e-06	0.000126	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CDKN2A—pancreatic cancer	5.79e-06	0.000429	CbGpPWpGaD
Epirubicin—Pharyngitis—Doxorubicin—pancreatic cancer	5.79e-06	0.000126	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—DPYD—pancreatic cancer	5.79e-06	0.000429	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—EGF—pancreatic cancer	5.79e-06	0.000429	CbGpPWpGaD
Epirubicin—Decreased appetite—Docetaxel—pancreatic cancer	5.77e-06	0.000126	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—GLP1R—pancreatic cancer	5.77e-06	0.000427	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	5.77e-06	0.000427	CbGpPWpGaD
Epirubicin—Headache—Fluorouracil—pancreatic cancer	5.76e-06	0.000125	CcSEcCtD
Epirubicin—Urinary tract disorder—Doxorubicin—pancreatic cancer	5.76e-06	0.000125	CcSEcCtD
Epirubicin—Oedema peripheral—Doxorubicin—pancreatic cancer	5.75e-06	0.000125	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Docetaxel—pancreatic cancer	5.73e-06	0.000125	CcSEcCtD
Epirubicin—Connective tissue disorder—Doxorubicin—pancreatic cancer	5.73e-06	0.000125	CcSEcCtD
Epirubicin—Fatigue—Docetaxel—pancreatic cancer	5.73e-06	0.000125	CcSEcCtD
Epirubicin—ABCC1—Metabolism—TYMP—pancreatic cancer	5.72e-06	0.000424	CbGpPWpGaD
Epirubicin—Urethral disorder—Doxorubicin—pancreatic cancer	5.72e-06	0.000124	CcSEcCtD
Epirubicin—Nausea—Irinotecan—pancreatic cancer	5.71e-06	0.000124	CcSEcCtD
Epirubicin—Pain—Docetaxel—pancreatic cancer	5.68e-06	0.000124	CcSEcCtD
Epirubicin—Constipation—Docetaxel—pancreatic cancer	5.68e-06	0.000124	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—DPYD—pancreatic cancer	5.68e-06	0.00042	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—GCG—pancreatic cancer	5.66e-06	0.000419	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	5.62e-06	0.000417	CbGpPWpGaD
Epirubicin—Visual impairment—Doxorubicin—pancreatic cancer	5.62e-06	0.000122	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—MYC—pancreatic cancer	5.61e-06	0.000416	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HEY2—pancreatic cancer	5.61e-06	0.000415	CbGpPWpGaD
Epirubicin—Nausea—Gemcitabine—pancreatic cancer	5.56e-06	0.000121	CcSEcCtD
Epirubicin—Erythema multiforme—Doxorubicin—pancreatic cancer	5.52e-06	0.00012	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—SLC2A2—pancreatic cancer	5.49e-06	0.000407	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—GAST—pancreatic cancer	5.47e-06	0.000406	CbGpPWpGaD
Epirubicin—Feeling abnormal—Docetaxel—pancreatic cancer	5.47e-06	0.000119	CcSEcCtD
Epirubicin—Nausea—Fluorouracil—pancreatic cancer	5.47e-06	0.000119	CcSEcCtD
Epirubicin—Eye disorder—Doxorubicin—pancreatic cancer	5.45e-06	0.000119	CcSEcCtD
Epirubicin—Tinnitus—Doxorubicin—pancreatic cancer	5.44e-06	0.000118	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—TP53—pancreatic cancer	5.44e-06	0.000403	CbGpPWpGaD
Epirubicin—Gastrointestinal pain—Docetaxel—pancreatic cancer	5.43e-06	0.000118	CcSEcCtD
Epirubicin—Flushing—Doxorubicin—pancreatic cancer	5.41e-06	0.000118	CcSEcCtD
Epirubicin—Cardiac disorder—Doxorubicin—pancreatic cancer	5.41e-06	0.000118	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—AGTR1—pancreatic cancer	5.4e-06	0.0004	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—SLC2A2—pancreatic cancer	5.39e-06	0.000399	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PIK3CB—pancreatic cancer	5.37e-06	0.000398	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	5.33e-06	0.000395	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PTGS2—pancreatic cancer	5.33e-06	0.000394	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	5.31e-06	0.000393	CbGpPWpGaD
Epirubicin—Angiopathy—Doxorubicin—pancreatic cancer	5.29e-06	0.000115	CcSEcCtD
Epirubicin—Immune system disorder—Doxorubicin—pancreatic cancer	5.27e-06	0.000115	CcSEcCtD
Epirubicin—Mediastinal disorder—Doxorubicin—pancreatic cancer	5.26e-06	0.000114	CcSEcCtD
Epirubicin—ABCC1—Disease—JAG2—pancreatic cancer	5.25e-06	0.000389	CbGpPWpGaD
Epirubicin—Abdominal pain—Docetaxel—pancreatic cancer	5.25e-06	0.000114	CcSEcCtD
Epirubicin—Body temperature increased—Docetaxel—pancreatic cancer	5.25e-06	0.000114	CcSEcCtD
Epirubicin—Chills—Doxorubicin—pancreatic cancer	5.24e-06	0.000114	CcSEcCtD
Epirubicin—Arrhythmia—Doxorubicin—pancreatic cancer	5.21e-06	0.000113	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—SCT—pancreatic cancer	5.19e-06	0.000384	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HEY1—pancreatic cancer	5.19e-06	0.000384	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—CDKN2A—pancreatic cancer	5.18e-06	0.000384	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MEN1—pancreatic cancer	5.18e-06	0.000383	CbGpPWpGaD
Epirubicin—Alopecia—Doxorubicin—pancreatic cancer	5.16e-06	0.000112	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—PIK3CD—pancreatic cancer	5.15e-06	0.000381	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	5.15e-06	0.000381	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SLC2A2—pancreatic cancer	5.14e-06	0.000381	CbGpPWpGaD
Epirubicin—Mental disorder—Doxorubicin—pancreatic cancer	5.11e-06	0.000111	CcSEcCtD
Epirubicin—Malnutrition—Doxorubicin—pancreatic cancer	5.08e-06	0.000111	CcSEcCtD
Epirubicin—Erythema—Doxorubicin—pancreatic cancer	5.08e-06	0.000111	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—MYC—pancreatic cancer	5.02e-06	0.000372	CbGpPWpGaD
Epirubicin—Flatulence—Doxorubicin—pancreatic cancer	5e-06	0.000109	CcSEcCtD
Epirubicin—Tension—Doxorubicin—pancreatic cancer	4.98e-06	0.000108	CcSEcCtD
Epirubicin—Dysgeusia—Doxorubicin—pancreatic cancer	4.97e-06	0.000108	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—CCK—pancreatic cancer	4.95e-06	0.000367	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SHH—pancreatic cancer	4.94e-06	0.000366	CbGpPWpGaD
Epirubicin—Nervousness—Doxorubicin—pancreatic cancer	4.93e-06	0.000107	CcSEcCtD
Epirubicin—Back pain—Doxorubicin—pancreatic cancer	4.91e-06	0.000107	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CCND1—pancreatic cancer	4.89e-06	0.000363	CbGpPWpGaD
Epirubicin—Hypersensitivity—Docetaxel—pancreatic cancer	4.89e-06	0.000107	CcSEcCtD
Epirubicin—Muscle spasms—Doxorubicin—pancreatic cancer	4.88e-06	0.000106	CcSEcCtD
Epirubicin—ABCC1—Disease—IAPP—pancreatic cancer	4.88e-06	0.000361	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	4.87e-06	0.000361	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CNR2—pancreatic cancer	4.82e-06	0.000357	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—GLP1R—pancreatic cancer	4.82e-06	0.000357	CbGpPWpGaD
Epirubicin—Vision blurred—Doxorubicin—pancreatic cancer	4.79e-06	0.000104	CcSEcCtD
Epirubicin—Asthenia—Docetaxel—pancreatic cancer	4.77e-06	0.000104	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—CCKAR—pancreatic cancer	4.75e-06	0.000352	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	4.72e-06	0.00035	CbGpPWpGaD
Epirubicin—Ill-defined disorder—Doxorubicin—pancreatic cancer	4.71e-06	0.000103	CcSEcCtD
Epirubicin—Pruritus—Docetaxel—pancreatic cancer	4.7e-06	0.000102	CcSEcCtD
Epirubicin—Anaemia—Doxorubicin—pancreatic cancer	4.69e-06	0.000102	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	4.69e-06	0.000347	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HSPA1B—pancreatic cancer	4.68e-06	0.000347	CbGpPWpGaD
Epirubicin—Agitation—Doxorubicin—pancreatic cancer	4.67e-06	0.000102	CcSEcCtD
Epirubicin—DHCR7—Metabolism—PTEN—pancreatic cancer	4.64e-06	0.000344	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GLP1R—pancreatic cancer	4.61e-06	0.000341	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—JAG2—pancreatic cancer	4.6e-06	0.000341	CbGpPWpGaD
Epirubicin—Malaise—Doxorubicin—pancreatic cancer	4.58e-06	9.97e-05	CcSEcCtD
Epirubicin—Vertigo—Doxorubicin—pancreatic cancer	4.56e-06	9.93e-05	CcSEcCtD
Epirubicin—Syncope—Doxorubicin—pancreatic cancer	4.55e-06	9.91e-05	CcSEcCtD
Epirubicin—Leukopenia—Doxorubicin—pancreatic cancer	4.55e-06	9.9e-05	CcSEcCtD
Epirubicin—Diarrhoea—Docetaxel—pancreatic cancer	4.54e-06	9.89e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—MEN1—pancreatic cancer	4.54e-06	0.000336	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—DPYD—pancreatic cancer	4.54e-06	0.000336	CbGpPWpGaD
Epirubicin—Palpitations—Doxorubicin—pancreatic cancer	4.49e-06	9.77e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—PIK3CB—pancreatic cancer	4.49e-06	0.000332	CbGpPWpGaD
Epirubicin—Loss of consciousness—Doxorubicin—pancreatic cancer	4.46e-06	9.72e-05	CcSEcCtD
Epirubicin—Cough—Doxorubicin—pancreatic cancer	4.43e-06	9.65e-05	CcSEcCtD
Epirubicin—Convulsion—Doxorubicin—pancreatic cancer	4.4e-06	9.58e-05	CcSEcCtD
Epirubicin—Dizziness—Docetaxel—pancreatic cancer	4.39e-06	9.56e-05	CcSEcCtD
Epirubicin—Hypertension—Doxorubicin—pancreatic cancer	4.38e-06	9.54e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CCND1—pancreatic cancer	4.38e-06	0.000324	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	4.34e-06	0.000321	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SHH—pancreatic cancer	4.33e-06	0.000321	CbGpPWpGaD
Epirubicin—Chest pain—Doxorubicin—pancreatic cancer	4.32e-06	9.41e-05	CcSEcCtD
Epirubicin—Myalgia—Doxorubicin—pancreatic cancer	4.32e-06	9.41e-05	CcSEcCtD
Epirubicin—Arthralgia—Doxorubicin—pancreatic cancer	4.32e-06	9.41e-05	CcSEcCtD
Epirubicin—Anxiety—Doxorubicin—pancreatic cancer	4.31e-06	9.38e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—SLC2A2—pancreatic cancer	4.3e-06	0.000319	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NOTCH4—pancreatic cancer	4.3e-06	0.000319	CbGpPWpGaD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	4.29e-06	9.35e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—IAPP—pancreatic cancer	4.27e-06	0.000317	CbGpPWpGaD
Epirubicin—Discomfort—Doxorubicin—pancreatic cancer	4.27e-06	9.3e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	4.26e-06	0.000316	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CD44—pancreatic cancer	4.25e-06	0.000315	CbGpPWpGaD
Epirubicin—Dry mouth—Doxorubicin—pancreatic cancer	4.23e-06	9.2e-05	CcSEcCtD
Epirubicin—Vomiting—Docetaxel—pancreatic cancer	4.22e-06	9.19e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—JAG1—pancreatic cancer	4.19e-06	0.00031	CbGpPWpGaD
Epirubicin—Rash—Docetaxel—pancreatic cancer	4.19e-06	9.12e-05	CcSEcCtD
Epirubicin—Dermatitis—Docetaxel—pancreatic cancer	4.18e-06	9.11e-05	CcSEcCtD
Epirubicin—Confusional state—Doxorubicin—pancreatic cancer	4.18e-06	9.1e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—CD44—pancreatic cancer	4.17e-06	0.000309	CbGpPWpGaD
Epirubicin—Headache—Docetaxel—pancreatic cancer	4.16e-06	9.06e-05	CcSEcCtD
Epirubicin—Oedema—Doxorubicin—pancreatic cancer	4.15e-06	9.02e-05	CcSEcCtD
Epirubicin—Anaphylactic shock—Doxorubicin—pancreatic cancer	4.15e-06	9.02e-05	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—TP53—pancreatic cancer	4.12e-06	0.000305	CbGpPWpGaD
Epirubicin—Infection—Doxorubicin—pancreatic cancer	4.12e-06	8.96e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	4.11e-06	0.000305	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTHLH—pancreatic cancer	4.1e-06	0.000304	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTCH1—pancreatic cancer	4.1e-06	0.000304	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	4.08e-06	0.000303	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GCG—pancreatic cancer	4.08e-06	0.000302	CbGpPWpGaD
Epirubicin—Shock—Doxorubicin—pancreatic cancer	4.08e-06	8.88e-05	CcSEcCtD
Epirubicin—Nervous system disorder—Doxorubicin—pancreatic cancer	4.07e-06	8.85e-05	CcSEcCtD
Epirubicin—Thrombocytopenia—Doxorubicin—pancreatic cancer	4.06e-06	8.83e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	4.05e-06	0.0003	CbGpPWpGaD
Epirubicin—Tachycardia—Doxorubicin—pancreatic cancer	4.05e-06	8.81e-05	CcSEcCtD
Epirubicin—Skin disorder—Doxorubicin—pancreatic cancer	4.03e-06	8.76e-05	CcSEcCtD
Epirubicin—Hyperhidrosis—Doxorubicin—pancreatic cancer	4.01e-06	8.72e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—GCG—pancreatic cancer	4e-06	0.000296	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CD44—pancreatic cancer	3.98e-06	0.000295	CbGpPWpGaD
Epirubicin—Anorexia—Doxorubicin—pancreatic cancer	3.95e-06	8.6e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—HSPA1A—pancreatic cancer	3.95e-06	0.000293	CbGpPWpGaD
Epirubicin—Nausea—Docetaxel—pancreatic cancer	3.95e-06	8.59e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—MYC—pancreatic cancer	3.93e-06	0.000291	CbGpPWpGaD
Epirubicin—Hypotension—Doxorubicin—pancreatic cancer	3.87e-06	8.43e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—STK11—pancreatic cancer	3.83e-06	0.000284	CbGpPWpGaD
Epirubicin—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	3.78e-06	8.22e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—STK11—pancreatic cancer	3.76e-06	0.000279	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SST—pancreatic cancer	3.75e-06	0.000278	CbGpPWpGaD
Epirubicin—Insomnia—Doxorubicin—pancreatic cancer	3.75e-06	8.16e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	3.74e-06	0.000277	CbGpPWpGaD
Epirubicin—Paraesthesia—Doxorubicin—pancreatic cancer	3.72e-06	8.1e-05	CcSEcCtD
Epirubicin—Dyspnoea—Doxorubicin—pancreatic cancer	3.7e-06	8.04e-05	CcSEcCtD
Epirubicin—Somnolence—Doxorubicin—pancreatic cancer	3.69e-06	8.02e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—JAG1—pancreatic cancer	3.67e-06	0.000272	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NOTCH3—pancreatic cancer	3.66e-06	0.000271	CbGpPWpGaD
Epirubicin—Dyspepsia—Doxorubicin—pancreatic cancer	3.65e-06	7.94e-05	CcSEcCtD
Epirubicin—Decreased appetite—Doxorubicin—pancreatic cancer	3.6e-06	7.84e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—SRC—pancreatic cancer	3.6e-06	0.000266	CbGpPWpGaD
Epirubicin—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	3.58e-06	7.79e-05	CcSEcCtD
Epirubicin—Fatigue—Doxorubicin—pancreatic cancer	3.57e-06	7.78e-05	CcSEcCtD
Epirubicin—Constipation—Doxorubicin—pancreatic cancer	3.54e-06	7.72e-05	CcSEcCtD
Epirubicin—Pain—Doxorubicin—pancreatic cancer	3.54e-06	7.72e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	3.53e-06	0.000261	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—MYC—pancreatic cancer	3.51e-06	0.00026	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—VEGFA—pancreatic cancer	3.5e-06	0.000259	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CNR1—pancreatic cancer	3.46e-06	0.000256	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—NRAS—pancreatic cancer	3.46e-06	0.000256	CbGpPWpGaD
Epirubicin—Feeling abnormal—Doxorubicin—pancreatic cancer	3.42e-06	7.43e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Doxorubicin—pancreatic cancer	3.39e-06	7.38e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CG—pancreatic cancer	3.36e-06	0.000249	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—GCG—pancreatic cancer	3.34e-06	0.000248	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CD44—pancreatic cancer	3.33e-06	0.000247	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—TYMS—pancreatic cancer	3.3e-06	0.000244	CbGpPWpGaD
Epirubicin—Urticaria—Doxorubicin—pancreatic cancer	3.29e-06	7.17e-05	CcSEcCtD
Epirubicin—Body temperature increased—Doxorubicin—pancreatic cancer	3.28e-06	7.13e-05	CcSEcCtD
Epirubicin—Abdominal pain—Doxorubicin—pancreatic cancer	3.28e-06	7.13e-05	CcSEcCtD
Epirubicin—DHCR7—Metabolism—PIK3CA—pancreatic cancer	3.28e-06	0.000243	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	3.26e-06	0.000242	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—TYMS—pancreatic cancer	3.23e-06	0.00024	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	3.23e-06	0.00024	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TGFB1—pancreatic cancer	3.21e-06	0.000238	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GCG—pancreatic cancer	3.2e-06	0.000237	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AGTR1—pancreatic cancer	3.19e-06	0.000236	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—STK11—pancreatic cancer	3.14e-06	0.000233	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SMAD4—pancreatic cancer	3.14e-06	0.000233	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HES1—pancreatic cancer	3.07e-06	0.000227	CbGpPWpGaD
Epirubicin—Hypersensitivity—Doxorubicin—pancreatic cancer	3.05e-06	6.65e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—STK11—pancreatic cancer	3e-06	0.000223	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—KRAS—pancreatic cancer	2.98e-06	0.000221	CbGpPWpGaD
Epirubicin—Asthenia—Doxorubicin—pancreatic cancer	2.97e-06	6.47e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CD—pancreatic cancer	2.95e-06	0.000219	CbGpPWpGaD
Epirubicin—Pruritus—Doxorubicin—pancreatic cancer	2.93e-06	6.38e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—TP53—pancreatic cancer	2.88e-06	0.000214	CbGpPWpGaD
Epirubicin—Diarrhoea—Doxorubicin—pancreatic cancer	2.84e-06	6.17e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.82e-06	0.000209	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SMAD4—pancreatic cancer	2.75e-06	0.000204	CbGpPWpGaD
Epirubicin—Dizziness—Doxorubicin—pancreatic cancer	2.74e-06	5.97e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—PIK3CA—pancreatic cancer	2.74e-06	0.000203	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HES1—pancreatic cancer	2.69e-06	0.000199	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TERT—pancreatic cancer	2.69e-06	0.000199	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—APOE—pancreatic cancer	2.68e-06	0.000199	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—AKT1—pancreatic cancer	2.68e-06	0.000198	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TP53—pancreatic cancer	2.65e-06	0.000196	CbGpPWpGaD
Epirubicin—Vomiting—Doxorubicin—pancreatic cancer	2.64e-06	5.74e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—APOE—pancreatic cancer	2.63e-06	0.000195	CbGpPWpGaD
Epirubicin—Rash—Doxorubicin—pancreatic cancer	2.61e-06	5.69e-05	CcSEcCtD
Epirubicin—Dermatitis—Doxorubicin—pancreatic cancer	2.61e-06	5.68e-05	CcSEcCtD
Epirubicin—Headache—Doxorubicin—pancreatic cancer	2.6e-06	5.65e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—TYMS—pancreatic cancer	2.58e-06	0.000191	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CB—pancreatic cancer	2.58e-06	0.000191	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HIF1A—pancreatic cancer	2.57e-06	0.00019	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TSC2—pancreatic cancer	2.56e-06	0.00019	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—HRAS—pancreatic cancer	2.53e-06	0.000187	CbGpPWpGaD
Epirubicin—ABCC1—Disease—APOE—pancreatic cancer	2.51e-06	0.000186	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	2.49e-06	0.000184	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CXCL8—pancreatic cancer	2.47e-06	0.000183	CbGpPWpGaD
Epirubicin—Nausea—Doxorubicin—pancreatic cancer	2.46e-06	5.36e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—PIK3CG—pancreatic cancer	2.42e-06	0.000179	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CG—pancreatic cancer	2.37e-06	0.000176	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TERT—pancreatic cancer	2.36e-06	0.000175	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PPARG—pancreatic cancer	2.34e-06	0.000173	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NOTCH1—pancreatic cancer	2.32e-06	0.000172	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PPARG—pancreatic cancer	2.29e-06	0.00017	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HIF1A—pancreatic cancer	2.25e-06	0.000167	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TSC2—pancreatic cancer	2.25e-06	0.000166	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EGF—pancreatic cancer	2.24e-06	0.000166	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—AKT1—pancreatic cancer	2.23e-06	0.000166	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—APOE—pancreatic cancer	2.2e-06	0.000163	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KDR—pancreatic cancer	2.16e-06	0.00016	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CD—pancreatic cancer	2.13e-06	0.000158	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—APOE—pancreatic cancer	2.1e-06	0.000156	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CD—pancreatic cancer	2.09e-06	0.000155	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NFKBIA—pancreatic cancer	2.05e-06	0.000152	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NOTCH1—pancreatic cancer	2.03e-06	0.00015	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CD—pancreatic cancer	1.99e-06	0.000147	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.99e-06	0.000147	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CG—pancreatic cancer	1.99e-06	0.000147	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—NRAS—pancreatic cancer	1.99e-06	0.000147	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EGF—pancreatic cancer	1.96e-06	0.000145	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CG—pancreatic cancer	1.9e-06	0.000141	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CB—pancreatic cancer	1.86e-06	0.000137	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTGS2—pancreatic cancer	1.84e-06	0.000136	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PPARG—pancreatic cancer	1.83e-06	0.000136	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CB—pancreatic cancer	1.82e-06	0.000135	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—EGFR—pancreatic cancer	1.81e-06	0.000134	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTGS2—pancreatic cancer	1.8e-06	0.000134	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CD—pancreatic cancer	1.75e-06	0.000129	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CB—pancreatic cancer	1.74e-06	0.000129	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTGS2—pancreatic cancer	1.72e-06	0.000127	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—KRAS—pancreatic cancer	1.71e-06	0.000127	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CD—pancreatic cancer	1.67e-06	0.000124	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTEN—pancreatic cancer	1.6e-06	0.000119	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTEN—pancreatic cancer	1.57e-06	0.000116	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.57e-06	0.000116	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CTNNB1—pancreatic cancer	1.54e-06	0.000114	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CB—pancreatic cancer	1.52e-06	0.000113	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTEN—pancreatic cancer	1.5e-06	0.000111	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCL8—pancreatic cancer	1.46e-06	0.000108	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CB—pancreatic cancer	1.45e-06	0.000108	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—HRAS—pancreatic cancer	1.45e-06	0.000108	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTGS2—pancreatic cancer	1.44e-06	0.000107	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CASP3—pancreatic cancer	1.4e-06	0.000104	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SRC—pancreatic cancer	1.39e-06	0.000103	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCND1—pancreatic cancer	1.36e-06	0.000101	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CTNNB1—pancreatic cancer	1.35e-06	9.99e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—STAT3—pancreatic cancer	1.34e-06	9.94e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NRAS—pancreatic cancer	1.34e-06	9.91e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MMP9—pancreatic cancer	1.32e-06	9.79e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTEN—pancreatic cancer	1.31e-06	9.74e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—AKT1—pancreatic cancer	1.28e-06	9.5e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTEN—pancreatic cancer	1.26e-06	9.3e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MYC—pancreatic cancer	1.25e-06	9.23e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TGFB1—pancreatic cancer	1.24e-06	9.21e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EGFR—pancreatic cancer	1.22e-06	9.03e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SRC—pancreatic cancer	1.22e-06	9.03e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—VEGFA—pancreatic cancer	1.19e-06	8.79e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—STAT3—pancreatic cancer	1.18e-06	8.71e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NRAS—pancreatic cancer	1.17e-06	8.69e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KRAS—pancreatic cancer	1.15e-06	8.53e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CA—pancreatic cancer	1.13e-06	8.38e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CA—pancreatic cancer	1.11e-06	8.21e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MYC—pancreatic cancer	1.09e-06	8.09e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TGFB1—pancreatic cancer	1.09e-06	8.07e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EGFR—pancreatic cancer	1.07e-06	7.91e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CA—pancreatic cancer	1.06e-06	7.84e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KRAS—pancreatic cancer	1.01e-06	7.48e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HRAS—pancreatic cancer	9.79e-07	7.25e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CA—pancreatic cancer	9.27e-07	6.87e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—AKT1—pancreatic cancer	9.24e-07	6.84e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—AKT1—pancreatic cancer	9.06e-07	6.71e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TP53—pancreatic cancer	8.97e-07	6.64e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CA—pancreatic cancer	8.86e-07	6.56e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—AKT1—pancreatic cancer	8.64e-07	6.4e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HRAS—pancreatic cancer	8.58e-07	6.35e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AKT1—pancreatic cancer	7.58e-07	5.61e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—AKT1—pancreatic cancer	7.24e-07	5.36e-05	CbGpPWpGaD
